We are live on ! Find out more
NRIX icon

Nurix Therapeutics
NRIX

106 hedge funds and large institutions have $568M invested in Nurix Therapeutics in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 46 increasing their positions, 30 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 30

10.07% more ownership

Funds ownership: 90.03% → 100.1% (+10%)

0% more capital invested

Capital invested by funds: $566M → $568M (+$2.5M)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

9% less funds holding

Funds holding: 117 → 106 (-11)

41% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 22

Holders
106
Holders Change
-11
Holders Change %
-9.4%
% of All Funds
1.79%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
13
Increased
46
Reduced
30
Closed
22
Calls
$2.14M
Puts
–
Net Calls
+$2.14M
Net Calls Change
+$111K

Top Buyers

1
DTC
Deep Track Capital
Connecticut
+$27.6M
2
BBA
Baker Bros. Advisors
New York
+$16.2M
3
BlackRock
BlackRock
New York
+$9.42M
4
WA
Wasatch Advisors
Utah
+$8.12M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$7.58M

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$8.95M
2
EAM
Eventide Asset Management
Massachusetts
-$8.12M
3
FCMI
Foresite Capital Management IV
California
-$4.01M
4
EC
EcoR1 Capital
California
-$3.56M
5
WP
Woodline Partners
California
-$3.07M
Name Holding Trade Value Shares
Change 		Change in
Stake
PM
26
Ponoi Management
California
$4.14M +$11 +1 +0%
N
27
Nuveen
North Carolina
$4.11M +$2.48M +219,194 +208%
Nomura Holdings
28
Nomura Holdings
Japan
$4.06M +$7.49K +661 +0.2%
HMC
29
Harvard Management Company
Massachusetts
$3.99M – – –
Bessemer Group
30
Bessemer Group
New Jersey
$3.86M – – –
Charles Schwab
31
Charles Schwab
California
$3.68M +$231K +20,404 +8%
WFA
32
WestHill Financial Advisors
California
$3.59M – – –
UBS AM
33
UBS AM
Illinois
$3.1M -$102K -8,967 -4%
Dimensional Fund Advisors
34
Dimensional Fund Advisors
Texas
$2.59M -$377K -33,223 -14%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$1.72M +$358K +31,581 +30%
JP Morgan Chase
36
JP Morgan Chase
New York
$1.64M +$102K +9,009 +7%
Renaissance Technologies
37
Renaissance Technologies
New York
$1.5M +$478K +42,200 +55%
JRP
38
Jasper Ridge Partners
California
$1.25M – – –
Bank of America
39
Bank of America
North Carolina
$1.11M +$400K +35,264 +67%
Ensign Peak Advisors
40
Ensign Peak Advisors
Utah
$1.07M – – –
Swiss National Bank
41
Swiss National Bank
Switzerland
$1M +$357K +31,500 +66%
Citigroup
42
Citigroup
New York
$954K +$568K +50,085 +199%
AllianceBernstein
43
AllianceBernstein
Tennessee
$928K +$457K +40,361 +123%
Rafferty Asset Management
44
Rafferty Asset Management
New York
$900K -$853K -75,231 -51%
JCIA
45
Jackson Creek Investment Advisors
Colorado
$879K +$624K +55,057 New
CSS
46
Cubist Systematic Strategies
Connecticut
$870K +$103K +9,103 +15%
RhumbLine Advisers
47
RhumbLine Advisers
Massachusetts
$799K +$335K +29,528 +88%
Manulife (Manufacturers Life Insurance)
48
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$770K -$60.6K -5,350 -8%
UBS Group
49
UBS Group
Switzerland
$752K -$1.01M -89,363 -60%
Ohio Public Employees Retirement System (OPERS)
50
Ohio Public Employees Retirement System (OPERS)
Ohio
$743K +$178K +15,697 +37%
1
2
3 4 5

NRIX Hedge Fund Activity: Q2 2022 in Review

106 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q2 2022, worth a combined $568M — up 0.44% from $566M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of NRIX and 13 opened new positions — a net loss of 9 holders — while 30 trimmed existing stakes and 46 added.

The largest buyer was Deep Track Capital, opening a new position worth an estimated $27.6M. The largest seller was Wellington Management Group, cutting an estimated $8.95M.

  • 106 institutional investors held Nurix Therapeutics (NRIX) as of Q2 2022, down from 117 in Q1 2022.
  • Funds reported $568M of Nurix Therapeutics stock for Q2 2022, up 0.44% quarter-over-quarter.
  • 13 funds opened new Nurix Therapeutics positions in Q2 2022 and 22 closed out, a net change of -9 holders.
  • The largest Nurix Therapeutics buyer in Q2 2022 was Deep Track Capital, an estimated $27.6M added.
  • The largest Nurix Therapeutics seller in Q2 2022 was Wellington Management Group, an estimated $8.95M sold.

Based on aggregated 13F filings for Q2 2022.